Sequence-Specific Signaling
AEDR is investigated within a family of short regulatory peptides. Direct DNA-interaction experiments found sequence-dependent behavior, not proof of selective cardiac gene repair. Peptide–DNA experiment.
Back to Peptide Library
Cardiac Bioregulator
Cardiogen
AEDR Tetrapeptide • Cardiac Tissue Research
Cardiogen is the synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR), associated with the Khavinson bioregulator research program. Its cardiac positioning comes from experimental work, including patent examples, rather than established treatment outcomes in people.
At a glance
Cardiogen Quick Reference
- Human injectable dose
- Members onlySign in to view dosing details.
- Research route
- SubQ injectionCommunity discussion
- Study duration
- Members onlySign in to view dosing details.
- Research focus
- Cardiac tissue and cell signalingSee cited research below
Overview
What Is Cardiogen?
Cardiogen is a four-amino-acid peptide with the sequence Ala-Glu-Asp-Arg, abbreviated AEDR. It belongs to the short-peptide bioregulator family. The original patent describes the same sequence and experimental myocardial applications. Original patent.
The cardiac story is preliminary. Animal and isolated-heart examples are useful for generating hypotheses, but a patent is not a clinical trial. We have not identified controlled human evidence establishing improvements in heart function, exercise capacity, or cardiovascular outcomes from Cardiogen.
Peer-reviewed molecular experiments also examine AEDR interactions with nucleic acids and proteins. Those studies help define possible molecular behavior; they do not show that a retail vial repairs heart tissue. Cardiogen should be distinguished from CardioGen-82, a diagnostic radiopharmaceutical generator with an unrelated purpose.
Mechanism
Cardiogen Mechanism of Action
Protein Interaction
Laboratory fluorescence experiments assessed interactions between short peptides, including Cardiogen, and proteins. These are molecular measurements rather than a demonstrated receptor pathway in humans. Peptide–protein study.
Myocardial Models
The original patent reports cardiac tissue and animal injury experiments. Its proposed protective actions need independent confirmation in peer-reviewed therapeutic studies.
Translation to People
A molecular or animal effect must still be connected to exposure, tissue delivery, and a meaningful clinical endpoint. Those steps remain unresolved for community injection protocols.
Research findings
Cardiogen Benefits
These are experimental research areas, not established benefits in people.
Evidence: laboratory and preclinical
Cardiac Tissue Interest
Myocardial models motivate further study. They do not establish improved ejection fraction or protection from a heart attack in people.
Cellular Stress Research
Experimental tissue responses may help researchers examine injury and recovery pathways. A clinical treatment effect has not been demonstrated.
Molecular Comparisons
AEDR provides a defined sequence for comparing peptide–DNA and peptide–protein behavior with other bioregulators.
Evidence Development
The useful next questions are independent replication, pharmacokinetics, and controlled human outcomes rather than more expansive marketing claims.
Protocol planning
Cardiogen Dosing Protocol
Members Access Only
Sign in or create a free account to view this content.
Preparation
Cardiogen Reconstitution
Reconstitution Example
10mg vial + 2mL BAC water
Result5mg/mL
Reconstitution steps
1
Prepare
Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.
2
Add diluent slowly
Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.
3
Dissolve gently
Swirl or roll the vial until the contents dissolve; do not shake.
4
Storage
Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.
N=1 reports
Cardiogen Community Experience
Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.
Discussion & Research Interest
- Bioregulator interest. Discussion focuses on cardiac tissue maintenance and healthy aging.
- Related compounds. Cardiogen is often discussed alongside vascular or other short-peptide bioregulators.
- Research priority. Formulation identity and objective endpoints are more useful than a general feeling of wellness.
Limitations & Mixed Interpretation
- Sparse reports. We do not have a reliable collection of formulation-specific outcomes to summarize.
- Attribution. Changes in exercise, medication, and other compounds confound reports.
- Clinical stakes. Subjective improvement cannot establish better cardiac function.
Stacking & synergy
Cardiogen Stacking & Synergy
No controlled human studies establish these combinations.
Cardiogen + Vesugen
A cardiac-versus-vascular research comparison. Different tissue positioning does not establish complementary effects or a validated combination.
Cardiogen + Humanin
Both attract interest around cellular stress. Their sequences and experimental mechanisms differ, and combination efficacy is unknown.
Cardiogen + Epitalon
A broader bioregulator pairing discussed in healthy-aging research. There is no controlled evidence validating a Cardiogen stack.
Safety notes
Cardiogen Side Effects & Safety
Cardiogen has a major human safety-data gap. Experimental cardiac claims should not be interpreted as evidence that it is safe for someone with heart disease.
Adverse effects and interactions require evaluation for the exact compound and formulation.
Safety & Tolerability
- No reliable human adverse-event frequency estimates are available.
- Injection-related irritation and ingredient hypersensitivity remain possible.
- A short amino-acid sequence does not establish safety.
Unresolved Questions
- Long-term exposure and cardiac electrophysiology have not been adequately characterized in people.
- Interactions with cardiac medicines are not established.
- Effects in active cancer and other complex conditions are uncertain.
Cardiogen Precautions
Avoid or discuss with a clinician if
- Known allergy to the peptide or excipients.
- Pregnancy, breastfeeding, or pediatric use without relevant safety evidence.
- Heart disease, unexplained palpitations, or a history of arrhythmia require qualified medical assessment.
Use caution with
- Prescription cardiovascular drugs and complex peptide stacks.
- Chest pain, fainting, or new breathlessness require prompt medical evaluation rather than experimental self-treatment.
Research status: Research-use material is not an established cardiovascular treatment, and no validated therapeutic regimen is presented here.
Final verdict
Peptide Protocols Verdict on Cardiogen
Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.
Our opinionated opinion
The name makes a big promise. What interests us is the defined AEDR sequence and the possibility of studying a short peptide in cardiac models. What keeps our enthusiasm measured is how much of the heart-specific story still rests on experimental and patent material.
We would put objective evidence ahead of anecdotes here: a better workout or less fatigue is not the same as improved cardiac function. This is a compound where the difference between an interesting hypothesis and a dependable intervention matters especially much.
Our C reflects that balance. Cardiogen belongs in a research library, but we would want substantially stronger human evidence before treating it as a cornerstone of cardiovascular support.